Carcinoma, Ductal, Breast

• 

  Subject Areas on Research

  • "Is it cancer or not?" A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ. 
  • A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. 
  • A SAGE (serial analysis of gene expression) view of breast tumor progression. 
  • A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis. 
  • Abbreviated screening protocol for breast MRI: a feasibility study. 
  • Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast. 
  • Accuracy of intraoperative gross examination of surgical margin status in women undergoing partial mastectomy for breast malignancy. 
  • Active Surveillance for DCIS: The Importance of Selection Criteria and Monitoring. 
  • Adjuvant hormonal therapy use among women with ductal carcinoma in situ. 
  • Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. 
  • Array comparative genomic hybridisation (aCGH) analysis of premenopausal breast cancers from a nuclear fallout area and matched cases from Western New York. 
  • Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. 
  • Association of breast cancer with the finding of atypical ductal hyperplasia at core breast biopsy. 
  • Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women. 
  • Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. 
  • Autofluorescence and diffuse reflectance properties of malignant and benign breast tissues. 
  • Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment. 
  • Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer. 
  • Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Breast MRI as an adjunct in the diagnosis of a carcinoma partially obscured on mammography. 
  • Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. 
  • Breast cancer in patients treated for Hodgkin's disease: clinical and pathological analysis of 76 cases in 63 patients. 
  • Breast conservation rates-barriers between tertiary care and community practice. 
  • Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features? 
  • Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells-in vitro and ex vivo study. 
  • Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. 
  • Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence-Guided System: A Nonrandomized Controlled Trial. 
  • Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors. 
  • Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes. 
  • Comparison of Reconstructive Outcomes in Breast Cancer Patients With Preexisting Subpectoral Implants: Implant-Sparing Mastectomy With Delayed Implant Exchange Versus Immediate Tissue Expander Reconstruction. 
  • Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. 
  • Cytologic evaluation of lumpectomy margins in patients with ductal carcinoma in situ: clinical outcome. 
  • Cytologic findings in a case of postirradiation angiosarcoma of the breast. 
  • DCIS with Microinvasion: Is It In Situ or Invasive Disease? 
  • DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival. 
  • De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ. 
  • De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer. 
  • Deep learning analysis of breast MRIs for prediction of occult invasive disease in ductal carcinoma in situ. 
  • Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. 
  • Diagnosis of breast cancer using diffuse reflectance spectroscopy: Comparison of a Monte Carlo versus partial least squares analysis based feature extraction technique. 
  • Diagnostic thoracic-computed tomography in radiotherapy for loco-regional recurrent breast carcinoma. 
  • Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas. 
  • Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast. 
  • Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. 
  • Disparity mapping applied to sonography of the breast: technical note. 
  • Do All Positive Margins in Breast Cancer Patients Undergoing a Partial Mastectomy Need to Be Resected? 
  • Does Breast Density Increase the Risk of Re-excision for Women with Breast Cancer Having Breast-Conservation Therapy? 
  • Does the proven benefit of mammography extend to breast cancer patients over age 70? 
  • Dosimetric comparison of 3D conformal, IMRT, and V-MAT techniques for accelerated partial-breast irradiation (APBI). 
  • Ductal Carcinoma In Situ in Pregnant Women. 
  • Ductal Carcinoma in Situ: State-of-the-Art Review. 
  • Early Adoption of the SSO-ASTRO Consensus Guidelines on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: Initial Experience from Memorial Sloan Kettering Cancer Center. 
  • Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients: Results of a Randomized Controlled Trial. 
  • Elevated Risk of Radiation Therapy-Associated Second Malignant Neoplasms in Young African-American Women Survivors of Stage I-IIIA Breast Cancer. 
  • Epithelial cells are an important source of tenascin in normal and malignant human breast tissue. 
  • Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast. 
  • Evaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI? 
  • Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. 
  • Extramedullary hematopoiesis during therapy with granulocyte colony-stimulating factor. 
  • Fatal re-expansion pulmonary edema associated with increased lung IL-8 levels following high-dose chemotherapy and autologous stem cell transplant. 
  • Frozen section evaluation of breast carcinoma sentinel lymph nodes: a retrospective review of 1,940 cases. 
  • Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case-control study. 
  • Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinoma. 
  • Genetic variants at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer. 
  • Genomic alterations and phenotype of large compared to small high-grade ductal carcinoma in situ. 
  • Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. 
  • Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization. 
  • Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. 
  • Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. 
  • HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. 
  • High frequency of aberrant p16(INK4A) expression in human breast cancer. 
  • Histological assessment of breast lesions identified exclusively by magnetic resonance. 
  • Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. 
  • Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk. 
  • Imaging Features of Patients Undergoing Active Surveillance for Ductal Carcinoma in Situ. 
  • Imaging-guided core needle biopsy of papillary lesions of the breast. 
  • Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP? 
  • Immunoreaction at 43 kDa with anti-ubiquitin antibody in breast neoplasms. 
  • Impact of laparoscopic staging in the treatment of pancreatic cancer. 
  • Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. 
  • Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). 
  • Incidence of Ductal Carcinoma In Situ in the United States, 2000-2014. 
  • Incidental minimal atypical lobular hyperplasia on core needle biopsy: correlation with findings on follow-up excision. 
  • Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. 
  • Intratumoral heterogeneity in primary breast carcinoma: study of concurrent parameters. 
  • Is Sentinel Lymph Node Biopsy Necessary for Ductal Carcinoma In Situ Patients Undergoing Mastectomy? 
  • Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins? 
  • Is there a correlation between breast cancer molecular subtype using receptors as surrogates and mammographic appearance? 
  • Is there an increased risk of local recurrence under the heart block in patients with left-sided breast cancer? 
  • Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. 
  • Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. 
  • Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. 
  • Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. 
  • Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. 
  • MR imaging of ductal carcinoma in situ. 
  • MRI predictors of tumor-positive margins after breast-conserving surgery. 
  • Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. 
  • Mammographic predictors of the presence and size of invasive carcinomas associated with malignant microcalcification lesions without a mass. 
  • Management of ductal carcinoma in situ. 
  • Medullary thyroid carcinoma metastatic to the breast: mammographic appearance. 
  • Microscopic localization of calcifications in and around breast carcinoma: a cautionary note for needle core biopsies. 
  • Modeling the natural history of ductal carcinoma in situ based on population data. 
  • Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. 
  • Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines. 
  • Molecular characterization of the tumor-suppressive function of nischarin in breast cancer. 
  • Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. 
  • Molecular markers of therapeutic resistance in breast cancer. 
  • Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. 
  • Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series. 
  • Negative predictive value of sonography with mammography in patients with palpable breast lesions. 
  • Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals. 
  • Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. 
  • Novel prognostic markers for patients with triple-negative breast cancer. 
  • Nuclear Snail1 and nuclear ZEB1 protein expression in invasive and intraductal human breast carcinomas. 
  • Oncologic Safety of Nipple-Sparing Mastectomy in Women with Breast Cancer. 
  • Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. 
  • Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis. 
  • Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. 
  • Paraneoplastic stiff-person syndrome: no tumor progression over 5 years. 
  • Performance assessment for radiologists interpreting screening mammography. 
  • Peritumoral expression of adipokines and fatty acids in breast cancer. 
  • Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ. 
  • Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. 
  • Predicting Upstaging of DCIS to Invasive Disease: Radiologists's Predictive Performance. 
  • Predicting a local recurrence after breast-conserving therapy by gene expression profiling. 
  • Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features. 
  • Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers. 
  • Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. 
  • Quality of Patient Decisions About Breast Reconstruction After Mastectomy. 
  • Quantitative spectral reflectance imaging device for intraoperative breast tumor margin assessment. 
  • Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y. 
  • Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs. 
  • Relationship between Background Parenchymal Enhancement on High-risk Screening MRI and Future Breast Cancer Risk. 
  • Reoperation for Margins After Breast Conservation Surgery: What's Old Is New Again. 
  • Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. 
  • Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. 
  • Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. 
  • Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. 
  • Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. 
  • Sonographic detection and sonographically guided biopsy of breast microcalcifications. 
  • Sonographically guided biopsy of suspicious microcalcifications of the breast: a pilot study. 
  • Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials. 
  • Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017. 
  • Surveillance Imaging after Primary Diagnosis of Ductal Carcinoma in Situ. 
  • Synergistic association of FOXP3+ tumor infiltrating lymphocytes with CCL20 expressions with poor prognosis of primary breast cancer: A retrospective cohort study. 
  • Telomerase activity in ductal carcinoma in situ and invasive breast cancer. 
  • The "banked" TRAM: a method to insure mastectomy skin-flap survival. 
  • The Association of Extent of Axillary Surgery and Survival in Women with N2-3 Invasive Breast Cancer. 
  • The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). 
  • The Effects of Surgery Type and Chemotherapy on Early-Stage Breast Cancer Patients' Quality of Life Over 2-Year Follow-up. 
  • The Landmark Series-Ductal Carcinoma in Situ: The Evolution of Treatment. 
  • The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer. 
  • The genomic relationship between primary breast carcinomas and their nodal metastases. 
  • Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. 
  • Updates on treating ductal carcinoma in situ: what's to know in 2021. 
  • Utilization of installation wound vacuum device for breast implant salvage: Approach and results. 
  • Validation of a breast cancer risk prediction model developed for Black women. 
  • What Can Molecular Diagnostics Add to Locoregional Treatment Recommendations for DCIS? 
  • β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. 
• 

  Keywords of People

  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology